Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application ...Middle East

SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the...

Hence then, the article about congratulations to dragon boat biopharmaceutical from sanyou biopharmaceuticals on the nmpa acceptance of the cldn 18 2 cd47 bsab clinical trial application was published today ( Sunday 26/06/2022 - 03:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application )

Also on site :

• Russian hockey legend Ovechkin refuses to wear LGBT tape
• After the Fire, Hope Valley Faces Its First Reckoning in 'When Calls the Heart' Season 13 Episode 3
• Merz criticizes Germans for getting sick too often